Editorials

Assessment of proteinuria in pregnancy

BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39540.657928.BE (Published 01 May 2008) Cite this as: BMJ 2008;336:968
  1. Lucy C Chappell, senior lecturer in maternal and fetal medicine,
  2. Andrew H Shennan, professor of obstetrics
  1. 1Division of Reproduction and Endocrinology, King’s College, London SE1 7EH
  1. lucy.chappell{at}kcl.ac.uk

    Urinary spot protein:creatinine ratio can reliably rule out proteinuria in pregnancy

    Pre-eclampsia is a global problem—it affects 2-8% of pregnancies, and an estimated 8.3 million women develop the disease each year. For developing countries, the priority is preventing maternal deaths from multiorgan complications of the disease. The difference in case fatality rates from eclampsia between developing countries and developed countries (5.2% v 0.72%) suggests that mortality is easily avoidable.1 In developed countries where death is rarer, research is directed towards improving prediction and prevention of pre-eclampsia and minimising morbidity. Accurate diagnosis is needed to accomplish this. In the accompanying systematic review, Côté and colleagues assess urinary spot protein:creatinine and albumin:creatinine ratios as diagnostic tests for significant proteinuria in women with hypertension in pregnancy.2

    Pre-eclampsia is a multiorgan syndrome, the clinical characteristics of which may include kidney, liver, and cerebral damage, an altered coagulant state, and fetal growth restriction.3 It is defined by two imperfect measures of end organ involvement—hypertension and proteinuria.4 Early blood markers of the disease can now be identified many weeks before these clinical manifestations,5 but antenatal diagnosis still relies on measuring blood pressure and urine …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe